David Fazzolare is a biotech, pharma and medical device patent attorney in the Intellectual Property practice of Morse, Barnes-Brown & Pendleton. David’s practice centers on preparing and prosecuting patent applications, developing and managing patent portfolios, and counseling clients (e.g., universities, research institutions, mulitnational biopharmaceutical companies, medical device companies, startups, etc.) on patentability, infringement, and freedom-to-operate during all phases of a product’s lifecycle, from concept to commercialization.
David’s patent experience covers a variety of complex and innovative inventions involving small molecule drugs, biologics, cell-based technologies (e.g., stem cells, reprogramming, differentiation, regenerative medicine, etc.), nutritional supplements, compositions of matter, medical devices (e.g., catheters, stents, grafts, etc.), drug delivery devices and formulations, nucleic acid- and protein-based technologies (e.g., gene, peptide, antibody, and RNA therapeutics (e.g., antisense, siRNA, miRNA, mRNA, etc.), mutant proteins, genome editing, etc.) and diagnostic tests. David also has experience counseling clients on the Hatch-Waxman Act and is closely following developments involving biosimilars under the Biologics Price Competition and Innovation Act.
David’s technological experience spans fields as diverse as immunology, oncology, cardiology, neurology, genetics, cell biology, molecular biology, and indications such as diabetes, metabolic disorders, cancer, neurodegenerative disorders (e.g., motor neuron diseases, such as spinal muscular atrophy and amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s disease), and pain.
Prior to joining MBBP, David worked as a patent attorney and associate at Greenberg Traurig, LLP, and as a patent agent at Myriad Genetics, Inc. David received his J.D. cum laude from J. Reuben Clark Law School, and received his B.S. summa cum laude in Pharmacology from SUNY at Stony Brook. David received his M.S. cum laude in Biotechnology from Johns Hopkins University in May 2012.
Publications by David A. Fazzolare
Second Biosimilar Application Filed Under BPCI Act by Celltrion
USPTO Guidance On Patentable Subject Matter: Impediment to Biotech Innovation?
Journal of Commercial Biotechnology
Will the Biosimilars Act Encourage Manufacturers to Bring Biosimilars to Market?
Food and Drug Policy Forum
Gaming the Biosimilars Act: Loopholes Allow Authorized Interchangeable Settlement Agreements to Delay Authentic Generic Competition up to 18 Months
FDA Udpate (July-Aug. 2010)
Strategic Management of International Life Sciences Patent Portfolios: Filing Strategies (Part I of III), J. Biolaw & Bus., Vol. 12, No. 3 (Oct 2009)
Comment, Wielding the Double-Edged Sword: Creating the Perception of a Chinese Enterprise to Obtain and Enforce Patent Protection in China, 5 BYU Int’l L. & Mgmt. Rev. 207 (2009)
A Common Sense Approach to Authorized Generics, J. Biolaw & Bus., Vol. 11, No. 3 (Sep 2008)
Teaches an elective course, Intellectual Property and Patent Law for Researchers, for the online MS in Pharmacology and Toxicology at Michigan State University
SUNY at Stony Brook
J. Reuben Clark Law School
Johns Hopkins University